[Correction of thrombocyte-vascular hemostasis in metabolic syndrome].
The purpose of the study was to evaluate the therapeutic effects of lovastatin and allicor on thrombocyte-vascular hemostasis in patients suffering from arterial hypertension (AH) with metabolic syndrome (MS). Twenty-two patients were administered lovastatin in a dose of 20 mg before sleep; 23 patients received allicor in a dose of two tablets or 150 mg twice a day. The therapy lasted one month in both groups. The dynamics of the following variables was evaluated: anthropometric parameters, blood lipid spectrum, lipid peroxidation in serum and thrombocytes, the antioxidative protectability of the lipid part of blood and thrombocytes, thrombocyte aggregation and their intravascular activity, and vascular hemostasis indices. The results were processed using Student coefficient, as well as system and correlation analysis. The study shows that lovastatin and, to a less degree, allicor, has a hypolipidemic effect, as well as a positive effect on peroxidation syndrome in patients suffering from AH with MS, optimizing thrombocyte-vascular hemostasis to the same degree. As a cheaper drug, allicor may be used widely to prevent thrombosis in patients with AH with MS. In order to lessen body mass in such patients, lovastatin and allicor should be applied together with non-drug means.
Medvedev
I N
IN
Gromnatskiĭ
N I
NI
Volobuev
I V
IV
Osipova
V M
VM
Storozhenko
M V
MV
D000328:Adult; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001792:Blood Platelets / Q000378:metabolism*; D005260:Female; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008148:Lovastatin / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged
D000924:Anticholesteremic Agents; D008148:Lovastatin